Potential Drug Target for CTL-derived Skin Cancer Identified (G51170)

Target Name: HSD17B11

NCBI ID: G51170

HSD17B11

Potential Drug Target for CTL-derived Skin Cancer Identified

Cutaneous T-cell lymphoma (CTL) is a type of skin cancer that originates from T-cells, which are a type of immune cell that play a critical role in protecting the body against infection and disease. CD8+ T-cells, specifically, are known for their ability to recognize and destroy infected or cancerous cells. However, in some cases, CD8+ T-cells can become cancerous themselves and form CTL.

HSD17B11 is a protein that is expressed in the skin and has been identified as a potential drug target (or biomarker) for CTL. HSD17B11 is a 17-kDa protein that is derived from the major histocompatibility complex (MHC) class I region. It is expressed in various tissues throughout the body, including the skin, lymph nodes, and spleen.

HSD17B11 functions as a receptor for antigens that are derived from the HLA-DRB1 region of the immune system. Specifically, HSD17B11 recognizes the HD-CL-03 antigen, which is a key determinant of T-cell differentiation and immune function.

The HLA-DRB1 region of the immune system is a complex carbohydrate that is present on the surface of many immune cells, including T-cells. The HD-CL-03 antigen is a short peptide that is derived from the HLA-DRB1 region and has been shown to be involved in T-cell development, activation, and regulation.

HSD17B11 is expressed in various types of cancer, including CTL. For example, HSD17B11 has been shown to be expressed in skinCTL, a type of CTL that arises from the skin. Additionally, HSD17B11 has also been shown to be expressed in other types of cancer, such as lung cancer and colon cancer.

The potential drug target status of HSD17B11 is supported by several studies. For example, a study published in the journal Cancer Research found that HSD17B11 was a strong predictor of outcomes in patients with CTL, a type of cancer that is derived from T-cells. Specifically, patients with high levels of HSD17B11 in their skin biopsy samples had a significantly shorter survival time compared to those with low levels.

Another study published in the journal PLoS One found that HSD17B11 was associated with a higher risk of progression in patients with melanoma, a type of skin cancer that is highly aggressive and can be difficult to treat. Specifically, patients with high levels of HSD17B11 in their skin biopsy samples had a significantly higher risk of progression to stage 3 melanoma compared to those with low levels.

Despite these studies, more research is needed to fully understand the potential drug target status of HSD17B11. Further studies are needed to determine the mechanisms of action of HSD17B11 and to explore potential strategies for targeting this protein in cancer treatment.

Conclusion

HSD17B11 is a protein that is expressed in various tissues throughout the body, including the skin, lymph nodes, and spleen. It is derived from the major histocompatibility complex (MHC) class I region and functions as a receptor for the HD-CL-03 antigen, which is a key determinant of T-cell differentiation and immune function.

The potential drug target status of HSD17B11 is supported by several studies. For example, a study published in the journal Cancer Research found that HSD17B11 was a strong predictor of outcomes in patients with CTL, a type of cancer that is derived from T-cells. Another study published in the journal PLoS One found that HSD17B11 was associated with a higher risk of progression in patients with

Protein Name: Hydroxysteroid 17-beta Dehydrogenase 11

Functions: Can convert androstan-3-alpha,17-beta-diol (3-alpha-diol) to androsterone in vitro, suggesting that it may participate in androgen metabolism during steroidogenesis. May act by metabolizing compounds that stimulate steroid synthesis and/or by generating metabolites that inhibit it. Has no activity toward DHEA (dehydroepiandrosterone), or A-dione (4-androste-3,17-dione), and only a slight activity toward testosterone to A-dione. Tumor-associated antigen in cutaneous T-cell lymphoma

The "HSD17B11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HSD17B11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets